Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 14/20 | 0.69 |
| ▸ | PDE2A | O00408 | 6/20 | 0.69 |
| ▸ | PTGDR | Q13258 | 9/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518236 | 0.95 | TBXA2R (0.78) | TBXA2RPDE2APTGDR | |
| SCHEMBL9518400 | 0.85 | TBXA2R (0.75) | TBXA2RPDE2APTGDR | |
| SCHEMBL9518358 | 0.83 | TBXA2R (0.85) | TBXA2RPDE2APTGDR | |
| SCHEMBL9518078 | 0.83 | TBXA2R (0.60) | TBXA2RPDE2APTGDR | |
| SCHEMBL6949873 | 0.83 | PDE2A (0.85) | TBXA2RPDE2APTGDRMEN1ALDH1A1 | |
| SCHEMBL9277313 | 0.82 | TBXA2R (1.00) | TBXA2RPDE2APTGDRTBXAS1 | |
| SCHEMBL9518853 | 0.82 | TBXA2R (0.85) | TBXA2RPDE2APTGDRTBXAS1MEN1 | |
| SCHEMBL9518334 | 0.80 | TBXA2R (0.79) | TBXA2RPDE2APTGDR | |
| SCHEMBL9518347 | 0.80 | TBXA2R (0.79) | TBXA2RPDE2APTGDR | |
| SCHEMBL10413594 | 0.80 | TBXA2R (0.96) | TBXA2RPDE2APTGDRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656141-B1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| EP-1656141-A1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LTD. (GB) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | PSEN1, PSEN2, APP | TBXA2R 1236/4885PDE2A 1086/4885PTGDR 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.